Home>BUSINESS

Eisai’s Midterm Strategy Focusing on Neurology, Oncology “Gradually Producing Results”: CEO Naito(Nov.2.2016)
Eisai CEO Haruo Naito |
Eisai’s strategy focusing on neurology and oncology set in its midterm business plan, dubbed “EWAY 2025” kicked off in April, “is gradually producing results,” stressed CEO Haruo Naito at an earnings briefing on October 31. “Particularly, we see steady progress in our pipeline,” he added ...
(LOG IN FOR FULL STORY)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected Apr.20
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers Apr.20
- Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup Apr.19
- Astellas Sells Agensys Research Facilities to Kite Apr.19
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit Apr.19